“2024 was a transformative year for Nyxoah (NYXH). We reported best-in-class outcomes from our DREAM pivotal study, completed our PMA submission with the FDA for Genio, and built a world-class U.S. commercial organization,” commented Olivier Taelman, Nyxoah’s CEO. “We believe an approval is still expected by the end of the first quarter, and we look forward to launching this innovative therapy to the millions of Americans suffering from moderate to severe OSA.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NYXH:
- Nyxoah Prepares for U.S. Launch Following Strong 2024 Performance
- Nyxoah to Announce Q4 and FY 2024 Financial Results
- Nyxoah to Present at Oppenheimer Healthcare Conference
- Nyxoah announces commercial launch of Genio system in the Middle East
- Nyxoah Launches Genio Therapy in Middle East with First UAE Implantation